Abstract:
:Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or renal impairment, insulin may be the treatment of choice when nonpharmacological measures prove inadequate. Insulin is also required for metabolic decompensation, that is, incipient or actual diabetic ketoacidosis, or non-ketotic hyperosmolar hyperglycaemia. Certain comorbidities, for example presentation with myocardial infarction during other acute intercurrent illness, may make insulin the best option. Oral antidiabetic agents should be initiated at a low dose and titrated up according to glycaemic response, as judged by measurement of glycosylated haemoglobin (HbA1c) concentration, supplemented in some patients by self monitoring of capillary blood glucose. The average glucose-lowering effect of the major classes of oral antidiabetic agents is broadly similar (averaging a 1-2% reduction in HbA1c), alpha-glucosidase inhibitors being rather less effective. Tailoring the treatment to the individual patient is an important principle. Doses are gradually titrated up according to response. However, the maximal glucose-lowering action for sulphonylureas is usually attained at appreciably lower doses (approximately 50%) than the manufacturers' recommended daily maximum. Combinations of certain agents, for example a secretagogue plus a biguanide or a thiazolidinedione, are logical and widely used, and combination preparations are now available in some countries. While the benefits of metformin added to a sulphonylurea were initially less favourable in the UKPDS, longer-term data have allayed concern. When considering long-term therapy, issues such as tolerability and convenience are important additional considerations. Neither sulphonylureas nor biguanides are able to appreciably alter the rate of progression of hyperglycaemia in patients with type 2 diabetes. Preliminary data suggesting that thiazolidinediones may provide better long-term glycaemic stability are currently being tested in clinical trials; current evidence, while encouraging, is not conclusive. Delayed progression from glucose intolerance to type 2 diabetes in high-risk individuals with glucose intolerance has been demonstrated with troglitazone, metformin and acarbose. However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals.
journal_name
Drugsjournal_title
Drugsauthors
Krentz AJ,Bailey CJdoi
10.2165/00003495-200565030-00005subject
Has Abstractpub_date
2005-01-01 00:00:00pages
385-411issue
3eissn
0012-6667issn
1179-1950pii
6535journal_volume
65pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::All male inhabitants of the city of Göteborg, who were born between 1915-1922 and 1924-1925 were included in the trial, and were 47 to 55 years of age on entry to the study in 1970 to 1973. One-third of these men were randomly allocated to an intervention group, whilst the other two-thirds acted as controls. Men of al...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198600311-00009
更新日期:1986-01-01 00:00:00
abstract::This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199753020-00001
更新日期:1997-02-01 00:00:00
abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01276-1
更新日期:2020-03-01 00:00:00
abstract::Our knowledge of the mechanisms of platelet-mediated thrombosis has increased dramatically over the last 40 years. This increased understanding has identified treatment strategies for acute coronary syndromes (ACS) by targeting key mediators of platelet activation and aggregation processes. Aspirin (acetylsalicylic ac...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11640880-000000000-00000
更新日期:2012-11-12 00:00:00
abstract::General anaesthesia is the reversible depression of central nervous system function. There is still no agreement over what constitutes depth of anaesthesia, and the clinical anaesthetist must thus titrate drug input according to clinical signs (heart rate, blood pressure, somatic movement, autonomic responses). The po...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199243010-00006
更新日期:1992-01-01 00:00:00
abstract::The effects of enalapril on clinical well-being, treadmill exercise performance, haemodynamic measurements, hormone levels, and plasma biochemistry in patients with moderate heart failure, were assessed in a 12-week placebo-controlled, double-blind study. Maintenance frusemide and digoxin treatment was continued throu...
journal_title:Drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00003495-198500301-00011
更新日期:1985-01-01 00:00:00
abstract::Management of renal cell carcinoma (RCC) has made considerable progress in recent years, and new emerging strategies are being developed. On the basis of the results of two randomised studies in the early 2000s, nephrectomy has now become the standard as cytoreductive surgery before embarking on systemic treatment wit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767090-00002
更新日期:2007-01-01 00:00:00
abstract::Testing for and treating sexually transmitted diseases (STDs) in pregnant women deserves special attention. Treatment possibilities are limited because of potential risks for the developing fetus, and because effects can differ in pregnant compared with non-pregnant women, re-infection may be missed because of the int...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200059030-00005
更新日期:2000-03-01 00:00:00
abstract::Amorolfine is a structurally unique, topically active antifungal agent, which possesses both fungistatic and fungicidal activity in vitro. Its spectrum of in vitro activity includes dermatophyte, dimorphic, some dematiaceous and filamentous fungi, and some yeasts. In clinical trials, application of amorolfine 5% nail ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199549010-00008
更新日期:1995-01-01 00:00:00
abstract::Despite advances in the understanding of the mechanism of cerebral injury during focal ischaemia, the best treatment of cerebral ischaemia is still prevention. The pathophysiological mechanisms that contribute to cerebral ischaemia are discussed relative to the many therapeutic interventions that have been attempted. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198835040-00005
更新日期:1988-04-01 00:00:00
abstract::A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of tr...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700341-00017
更新日期:1987-01-01 00:00:00
abstract::Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666120-00009
更新日期:2006-01-01 00:00:00
abstract::Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0234-4
更新日期:2014-07-01 00:00:00
abstract::Coronary artery disease and acute myocardial infarction still represent the leading cause of mortality in developed countries. Therefore, great efforts have been made in the last decades to improve reperfusion strategies and adjunctive antithrombotic therapies. In fact, despite optimal epicardial recanalisation, a lar...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0425-7
更新日期:2015-07-01 00:00:00
abstract::When to treat the patient who presents with ocular hypertension has been a question that has 'stumped' the ophthalmic community for decades. Population-based studies and intervention trials have provided the basis for understanding why we consider treating such patients. Although the EGPS (European Glaucoma Prevention...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666080-00001
更新日期:2006-01-01 00:00:00
abstract::Bacterial meningitis in adults is a severe disease with high fatality and morbidity rates. Experimental studies have shown that the inflammatory response in the subarachnoid space is associated with an unfavourable outcome. In these experiments, corticosteroids, and in particular dexamethasone, were able to reduce the...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666040-00002
更新日期:2006-01-01 00:00:00
abstract::The emergence of antibiotic resistance is primarily due to excessive and often unnecessary use of antibiotics in humans and animals. Risk factors for the spread of resistant bacteria in hospitals and the community can be summarised as over-crowding, lapses in hygiene or poor infection control practices. Increasing ant...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199855030-00001
更新日期:1998-03-01 00:00:00
abstract::The discovery of immune inhibitory checkpoints has revolutionized the approach to the systemic treatment of cancer. The programmed death 1 (PD-1) inhibitory checkpoint, in particular, has played a key role in understanding how certain cancers can evade immune surveillance. Blocking the interaction between the PD-1 rec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0376-z
更新日期:2015-04-01 00:00:00
abstract::Sitagliptin (Januvia(®), Xelevia™, Glactiv(®), Tesavel(®)) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Numerous randomized placebo- or active comparator-c...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0169-1
更新日期:2014-02-01 00:00:00
abstract::Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) without a targetable molecular abnormality. However, the majority of patients with NSCLC will ultimately develop resistance to initial platinu...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0628-6
更新日期:2016-09-01 00:00:00
abstract::Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis, while maintaining low...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363220-00015
更新日期:2003-01-01 00:00:00
abstract::Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11532200-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::Losartan/hydrochlorothiazide (HCTZ) [Hyzaar(R)] is a fixed-dose combination of the angiotensin II receptor antagonist (angiotensin receptor blocker [ARB]) losartan and the thiazide diuretic HCTZ. It is indicated for the treatment of hypertension (including as initial therapy in severe hypertension) and for stroke risk...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200969090-00008
更新日期:2009-06-18 00:00:00
abstract::Acute infectious diarrhoea is the major killer of children in the Third World. It is also the principal cause of malnutrition in children under 5 years of age. More than 4 million children die each year of diarrhoea and its complications. Acute diarrhoea kills by causing dehydration, which leads to hypovolaemia and me...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198800364-00003
更新日期:1988-01-01 00:00:00
abstract::Pruritus is an unpleasant sensation that provokes an urge to scratch. Many stimuli (notably histamine) are able to induce pruritus. The neural conduction of the itch sensation from the free unmyelinated nerve endings to the central nervous system mainly occurs on unmyelinated C fibres and the anterolateral spinothalam...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199039020-00005
更新日期:1990-02-01 00:00:00
abstract::Acarbose delays digestion of complex carbohydrates and disaccharides to absorbable monosaccharides, by reversibly inhibiting alpha-glucosidases within the intestinal brush border, thereby attenuating postprandial blood glucose peaks. Clinical trials have demonstrated that acarbose generally improves glycaemic control ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199346060-00007
更新日期:1993-12-01 00:00:00
abstract::Involuntary infertility is an increasing problem in this era of delayed childbearing. Fortunately, many advances have been made recently in the medical and surgical treatment of infertility. This article reviews the principal aetiologies of infertility and their treatments, and focuses on the current and future uses o...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198632020-00004
更新日期:1986-08-01 00:00:00
abstract::Outpatient parenteral antibiotic therapy (OPAT) programmes are effective, well tolerated and economically advantageous in carefully selected patient populations. Inclusion criteria for patient selection for OPAT include good clinical appearance and uncomplicated infection. By virtue of their favourable microbiological...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200059003-00003
更新日期:2000-01-01 00:00:00
abstract::The fluoroquinolones have been shown to be active in vitro against many mycobacterial species, including most strains of Mycobacterium tuberculosis complex and M. fortuitum, and some strains of M. kansasii, M. avium-intracellulare (MAI) complex and M. leprae. Ciprofloxacin, ofloxacin and sparfloxacin are the best stud...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958002-00004
更新日期:1999-01-01 00:00:00
abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01417-6
更新日期:2020-11-01 00:00:00